Logo

American Heart Association

  2
  0


Final ID: Sa3104

Inactive Matrix Gla Protein and Cardiovascular Outcomes: the Multi-Ethnic Study of Atherosclerosis

Abstract Body (Do not enter title and authors here): Background: Matrix Gla protein (MGP) inhibits arterial calcification. Higher inactive MGP, dephosphorylated-uncarboxylated (dp-ucMGP), is positively associated with vascular calcification, possibly portending cardiovascular events. The objective was to determine the association of dp-ucMGP with incident cardiovascular disease (CVD) events and mortality in the Multi-Ethnic Study of Atherosclerosis (MESA).
Methods: MESA is a cohort study of 45-84 year-old individuals enrolled between 2000-02 with adjudicated outcomes through 2019. Dp-ucMGP was measured at baseline in n=2663 participants with cardiac computed tomography at Exams 1 (2000-02) and 5 (2010-12). Using age-stratified Cox proportional hazard models, adjusted for sex, race-ethnicity, body mass index, systolic blood pressure, statin use, anti-hypertensive medication use, smoking status, physical activity, alcohol use, diabetes, high density lipoprotein, low density lipoprotein, triglycerides, phosphate, and estimated glomerular filtration rate, we determined the association of dp-ucMGP with risk of all CVD (mean follow-up 16 + 4 years), hard CVD (17 + 3 years), hard CHD (17 + 3 years), and all-cause mortality (18 + 2 years).
Results: The youngest age quartile (45-53-years-old) with higher dp-ucMGP levels (520-2934 pmol/L) had an increased risk of all CVD (HR 3.01 [95% CI 1.56, 5.80], p=0.001), hard CVD (HR 2.78 [95% CI 1.29, 6.02], p=0.009), hard CHD (HR 3.37 [95% CI 1.29, 8.81], p=0.013) and all-cause mortality (HR 2.69 [95% CI 1.06, 6.79], p=0.037) compared to dp-ucMGP levels between 150-519 pmol/L in maximally adjusted models. There was no relationship with any outcomes for the other age quartiles (Table).
Conclusions: Middle aged individuals with elevated dp-ucMGP levels (>520 pmol/L) had an increased risk of incident CVD, CHD, and all-cause mortality.
  • Berlot, Ashley  ( Albert Einstein College of Medicine , Bronx , New York , United States )
  • Bortnick, Anna  ( WEILER HOSP , Bronx , New York , United States )
  • Fu, Xueyan  ( TUFTS UNIVERSITY , Boston , Massachusetts , United States )
  • Shea, Kyla  ( TUFTS UNIVERSITY , Boston , Massachusetts , United States )
  • Tracy, Russell  ( UNIVERSITY VERMONT , Colchester , Vermont , United States )
  • Budoff, Matthew  ( LUNDQUIST INSTITUTE , Torrance , California , United States )
  • Kim, Ryung  ( Albert Einstein College of Medicine , Bronx , New York , United States )
  • Naveed, Mahim  ( San Francisco VA , San Francisco , California , United States )
  • Booth, Sarah  ( Tufts University , Boston , Massachusetts , United States )
  • Kizer, Jorge  ( San Francisco VA , San Francisco , California , United States )
  • Author Disclosures:
    Ashley Berlot: DO NOT have relevant financial relationships | Anna Bortnick: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Getinge, Honoraria to Institution:Past (completed) ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):CSL Behring:Past (completed) ; Other (please indicate in the box next to the company name):Zoll, Honoraria to Institution:Past (completed) | Xueyan Fu: DO NOT have relevant financial relationships | Kyla Shea: DO NOT have relevant financial relationships | Russell Tracy: No Answer | Matthew Budoff: DO have relevant financial relationships ; Researcher:General Electric:Active (exists now) | Ryung Kim: No Answer | Mahim Naveed: DO NOT have relevant financial relationships | Sarah Booth: No Answer | JORGE KIZER: DO have relevant financial relationships ; Individual Stocks/Stock Options:Abbott:Past (completed) ; Individual Stocks/Stock Options:Pfizer:Past (completed) ; Individual Stocks/Stock Options:Merck:Past (completed) ; Individual Stocks/Stock Options:Medtronic:Past (completed) ; Individual Stocks/Stock Options:Lilly:Past (completed) ; Individual Stocks/Stock Options:Johnson & Johnson:Past (completed) ; Individual Stocks/Stock Options:Bristol Myers Squibb:Past (completed) ; Individual Stocks/Stock Options:AbbVie:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Clinical Prediction, Prognosis, and Decision-Making

Saturday, 11/16/2024 , 02:00PM - 03:00PM

Abstract Poster Session

More abstracts on this topic:
A Pharmacovigilance Study of Bempedoic Acid: Balancing Risks and Benefits

Khadka Sulochana, Timilsina Bibek, Matai Pallavi, Sharma Seema, Rajak Kripa, Calderon Barahona Gabriela, Oli Seema

ACUTE ISCHEMIC STROKE IN YOUNG CANNABIS USERS: A NATIONWIDE ANALYSIS

Joseph Varughese Vivek, Anil Peethambar Gowri, Jayaraj Ranjini Nived, Mummadisetty Anvitha

You have to be authorized to contact abstract author. Please, Login
Not Available